Literature DB >> 15879022

Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.

Kristina Abel1, Yichuan Wang, Linda Fritts, Eleonora Sanchez, Eugene Chung, Patricia Fitzgerald-Bocarsly, Arthur M Krieg, Christopher J Miller.   

Abstract

To determine if deoxycytidyl-deoxyguanosine oligonucleotides (CpG ODN) can be used effectively as nonspecific inducers of innate immune defenses for preventative or therapeutic interventions in infectious disease models for nonhuman primates, the present study evaluated the response of rhesus monkey peripheral blood mononuclear cells to three different synthetic CpG ODN classes by defining the cytokine gene expression patterns and by characterizing IFN-alpha/beta responses. Depending on the type and dose of CpG ODN used for stimulation, distinct gene expression patterns were induced. CpG ODN class A (CpG-A ODN) and CpG-C ODN, but not CpG-B ODN, were potent inducers of alpha interferon (IFN-alpha), and this response was due to IFN-alpha production by TLR9-positive plasmacytoid dendritic cells. Importantly, there was a dose-dependent increase in IFN-alpha responses to CpG-A ODN but a dose-dependent decrease in IFN-alpha responses by CpG-B ODN. The most sustained IFN-alpha response was induced by CpG-A ODN and was associated with a stronger induction of interferon regulatory factor 7 and the induction of several interferon-stimulated genes. In contrast, and independent of the dose, CpG-B ODN were the weakest inducers of IFN-alpha but the most potent inducers of proinflammatory cytokines. CpG-C ODN induced cytokine gene expression patterns that were intermediate between those of CpG-A and CpG-B ODN. Thus, the different types of CpG ODN induce different post-TLR9 signaling pathways that result in distinct cytokine gene expression patterns. Based on these findings, A and C class CpG ODN, but not B class CpG ODN, may be particularly suited for use as therapeutic or prophylactic antiviral interventions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879022      PMCID: PMC1112080          DOI: 10.1128/CDLI.12.5.606-621.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  70 in total

Review 1.  Links between innate and adaptive immunity via type I interferon.

Authors:  Agnes Le Bon; David F Tough
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

Review 2.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

3.  Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes.

Authors:  B J Barnes; P A Moore; P M Pitha
Journal:  J Biol Chem       Date:  2001-04-12       Impact factor: 5.157

4.  The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

5.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

6.  Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

Authors:  T R Jones; N Obaldia; R A Gramzinski; Y Charoenvit; N Kolodny; S Kitov; H L Davis; A M Krieg; S L Hoffman
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

7.  Reconstitution of virus-mediated expression of interferon alpha genes in human fibroblast cells by ectopic interferon regulatory factor-7.

Authors:  W S Yeow; W C Au; Y T Juang; C D Fields; C L Dent; D R Gewert; P M Pitha
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

8.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 10.  The challenge of emerging and re-emerging infectious diseases.

Authors:  David M Morens; Gregory K Folkers; Anthony S Fauci
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

View more
  22 in total

1.  Characterization of plasmacytoid dendritic cells in bone marrow of pig-tailed macaques.

Authors:  R Keith Reeves; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

2.  Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Duc H Do; Veronica M Holmes; Mary K Howett; Mark G Lewis; Alina C Boesteanu; Sefik S Alkan; Peter D Katsikis
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

3.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  The early interferon alpha subtype response in infant macaques infected orally with SIV.

Authors:  Juliet Easlick; Richard Szubin; Samantha Lantz; Nicole Baumgarth; Kristina Abel
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

5.  Activation of Innate Immune Responses by a CpG Oligonucleotide Sequence Composed Entirely of Threose Nucleic Acid.

Authors:  Margaret J Lange; Donald H Burke; John C Chaput
Journal:  Nucleic Acid Ther       Date:  2018-12-11       Impact factor: 5.486

6.  Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation.

Authors:  Cornelia Gujer; Christopher Sundling; Robert A Seder; Gunilla B Karlsson Hedestam; Karin Loré
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

7.  The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells.

Authors:  Rivka Melamed; Ella Rosenne; Marganit Benish; Yael Goldfarb; Ben Levi; Shamgar Ben-Eliyahu
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

8.  Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques.

Authors:  V Ann Stewart; Shannon McGrath; Arthur M Krieg; Noelle S Larson; Evelina Angov; Christopher L Smith; Thomas G Brewer; D Gray Heppner
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

9.  Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.

Authors:  Yichuan Wang; Shelley A Blozis; Michael Lederman; Arthur Krieg; Alan Landay; Christopher J Miller
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

Review 10.  T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

Authors:  David J Kahler; Andrew L Mellor
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.